Background
Methods
Search methodology
Criteria for the review
Statistical analysis
Results
Characteristics of included studies
Study | Year | Country | Study design | Number (Male) | Tumor stage | Cut-off for high CONUT group | Prevalence of high CONUT score | End points | Qualitya |
---|---|---|---|---|---|---|---|---|---|
Takagi et al. [11] | 2017 | Japan | Retrospective Single center | 295 (241) | I: 36 II: 126 III: 92 IV: 41 | ≥3 | 40.0% | OS RFS | 7 |
Harimoto et al. [12] | 2017 | Japan | Retrospective Single center | 357 (270) | I: 58 II: 187 III: 93 IV: 19 | ≥4 | 19.3% | OS RFS | 6 |
Takagi et al. [13] | 2018 | Japan | Retrospective Single center | 331 (269) | I + II: 185 III + IV: 146 | ≥5 | 9.1% | Complications | 6 |
Harimoto et al. [14] | 2018 | Japan | Retrospective Multi-center | 2461 (1785) | I + II: 1437 III + IV: 1024 | ≥4 | 21.9% | OS RFS | 6 |
Li et al. [15] | 2018 | China | Retrospective Single center | 1334 (1136) | n.a. | ≥8b | 49.4% | Complications | 8 |
Wang et al. [16] | 2018 | China | Retrospective Single center | 209 (172) | BCLC stage A: 126 B: 40 C: 43 | ≥3 | 34.5% | OS RFS PHR | 6 |
Lin et al. [17] | 2019 | China | Retrospective Single center | 380 (333) | I + II: 304 III + IV: 76 | ≥2 | 49.2% | OS RFS | 8 |
Reported outcomes
Study | Complications | Mortality | Recurrence-free survival | Overall survival |
---|---|---|---|---|
Takagi et al. [11] | Major (CDc ≥ III): 15 vs 14% (P = 0.79) | n.a. | 5-year: 27.9 vs 41.4% (P = 0.011) HR 1.64 (1.15–2.30), P = 0.006a | 5-year: 61.9 vs 74.9% (P = 0.006) HR 2.50 (1.47–4.23), P = 0.001a |
Harimoto et al. [12] | Major (CDc ≥ III): 20.3 vs 14.9% (P = 0.36) | n.a. | 5-year: 8.8 vs 38.0% (P < 0.01) HR 1.51 (1.06–2.15), P = 0.02b | 5-year: 47.6 vs 78.0% (P < 0.01) HR 2.16 (1.25–3.72), P = 0.03a |
Takagi et al. [13] | Overall (CDc ≥ II): 56.7 vs 45.5% (P = 0.24) Major (CDc ≥ III): 23.3 vs 13.6% (P = 0.15) | 10.0 vs 1.3% (P = 0.002) OR 9.41 (1.15–77.4), P = 0.038a | n.a. | n.a. |
Harimoto et al. [14] | Major (CDc ≥ III): 17.7 vs 11.0% (P < 0.01) | n.a. | HR 1.219 (1.06–1.40), P = 0.006a | HR 1.223 (1.06–1.41), P = 0.006a |
Li et al. [15] | Major (CDc ≥ III): 15.6 vs 6.2% (P < 0.001) OR 2.05 (1.37–3.01), P < 0.001a | 2.6 vs 0.4% (P = 0.001) | n.a. | n.a. |
Wang et al. [16] | Overall: 74.3 vs 59.3% (P = 0.029) | n.a. | 5-year: 10.0 vs 9.6% (P = 0.001) HR 1.54 (1.10–2.16), P = 0.011a | 5-year: 31.3 vs 44.0% (P < 0.001) HR 1.62 (1.05–2.51), P = 0.03a |
Lin et al. [17] | Overall (CDc ≥ II): 29.4 vs 23.3% (P = 0.177) | n.a. | 5-year: 37.2 vs 47.6% (P = 0.016) HR 1.36 (1.00–1.85), P = 0.052a | 5-year: 66.7 vs 82.8% (P < 0.001) HR 2.40 (1.74–4.25), P = 0.001a |